Mandate

Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue

April 01, 2011

Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.

Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.

Related

Vinge advises Ambea on the acquisition of Validia

Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025

Vinge has advised Röko in connection with its listing on Nasdaq Stockholm

Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.
March 11, 2025

Vinge has advised Ingrid Capacity in new co-operation with Locus Energy, one of SEB Nordic Energy's portfolio companies

Vinge has advised Ingrid Capacity in connection with a new project together with Locus Energy, a leading Nordic energy infrastructure company owned by SEB Asset Management's SEB Nordic Energy fund, to develop Finland's largest and one of the Nordic region's largest battery storage systems.
March 07, 2025